Previous 10 | Next 10 |
FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy - RAINBOWFISH study interim results showed that after treatment with Evrysdi pre-symptomatic infants with spinal muscular atrophy achieved same motor mile...
PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community - 2022 grant program will focus on Innovation and Transition to Adulthood initiatives - - Submissions due on March 18, 2022...
PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program - One-year fellowship provides diverse work experiences across PTC's business areas - PR Newswire SOUTH PLAINFIELD, N.J. , Jan. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASD...
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference - $536 million un...
Waylivra™ Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil - Additional application submitted to ANVISA for a new indication to treat familial partial lipodystrophy - PR Newswire SOUTH PLAINFIELD, N.J. , ...
PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference PR Newswire SOUTH PLAINFIELD, N.J. , Jan. 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview a...
Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform -- Results published in Nature Communications -- -- Description of novel splicing mechanism causing inhibition of HTT gene expression ...
Evrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery PR Newswire SOUTH PLAINFIELD, N.J. , Dec. 6, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi ® (risdiplam) has rece...
PTC Therapeutics, Inc. (PTCT) Q3 2021 Earnings Conference Call October 28, 2021 4:30 PM ET Company Participants Kylie O'Keefe – Head-Investor Relations Stuart Peltz – Chief Executive Officer Matthew Klein – Chief Development Officer Eric Pauwels – Chief Business Of...
Image source: The Motley Fool. PTC Therapeutics Inc (NASDAQ: PTCT) Q3 2021 Earnings Call Oct 28, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: PTC Therapeutics Inc (PTCT) Q3 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....